RxDoctor Payments Data

Brian Forrest

Family Medicine · Apex, NCNPI 1376540112

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $296,450 of the $397,532 with a category attached, or 74.6%. Amgen accounts for 93.0% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $103,800, more than ten times the $459 reported in 2019. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$397,532in general payments, 2019–2025

Across 785 payments — averaging $506.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$370K
  • E.r. Squibb & Sons, L.L.C.$18K
  • Pfizer$8K
  • Regeneron$432
  • Novo Nordisk$386
  • AbbVie$328
  • plus $534 from 12 others

What the payments were for

  • Consulting fees$25,5426%
  • Speaking & faculty fees$296,45075%
  • Travel & lodging$60,45915%
  • Food & beverage$15,0814%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$397,532 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$49,199
FarxigaDapagliflozin Propanediol17$18,639
EliquisApixaban22$12,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,932
Nebivolol Hcl67$3,242
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide53$2,294
Celecoxib95$1,881
Rosuvastatin Calcium118$1,773
Levothyroxine Sodium81$1,059
Olmesartan Medoxomil64$948
Escitalopram Oxalate58$722
Metformin Hcl58$643
Pantoprazole Sodium65$587
Albuterol Sulfate HfaAlbuterol Sulfate11$525
Dutasteride16$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$386$49,19941 claims
AstraZenecaFarxiga$76$18,63917 claims
PfizerEliquis$8,250$12,81722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Apex

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →